Drug intelligence / Profile preview

LTX-009

Development stage: Preclinical
Lead developer: Leal Therapeutics
Modality: Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

LTX-009 is an antibody-oligonucleotide conjugate (AOC) in preclinical development by Leal Therapeutics for the treatment of Alzheimer's disease. The therapeutic is designed to target multiple undisclosed pathways involved in the pathogenesis of Alzheimer's disease, leveraging the precision of antibody-mediated delivery combined with oligonucleotide-based modulation.

Beyond the preview

Go deeper on LTX-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTX-009.

Explore the full profile